Related Experiment Video
Updated: Jun 18, 2025
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression
Alexis E Carey1, Ashani T Weeraratna1
1Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract:
Melanoma is the deadliest form of skin cancer in the United States, with its incidence rates rising in older populations. As the immune system undergoes age-related changes, these alterations can significantly influence tumor progression and the effectiveness of cancer treatments. Recent advancements in understanding immune checkpoint molecules have paved the way for the development of innovative immunotherapies targeting solid tumors. However, the aging tumor microenvironment can play a crucial role in modulating the response to these immunotherapeutic approaches. This review seeks to examine the intricate relationship between age-related changes in the immune system and their impact on the efficacy of immunotherapies, particularly in the context of melanoma. By exploring this complex interplay, we hope to elucidate potential strategies to optimize treatment outcomes for older patients with melanoma, and draw parallels to other cancers.
Insights
Aging alters the immune system, impacting melanoma progression and immunotherapy effectiveness in older adults. This review explores strategies to improve cancer treatment outcomes for this demographic.
Area of Science:
- Oncology
- Immunology
- Gerontology
Background:
- Melanoma incidence is increasing in older adults.
- Age-related immune system changes affect cancer progression and treatment.
- Immune checkpoint inhibitors offer new immunotherapy options for solid tumors.
Purpose of the Study:
- To review the relationship between immune system aging and immunotherapy efficacy in melanoma.
- To identify strategies for optimizing melanoma treatment in older patients.
- To draw parallels between melanoma and other age-related cancer immunotherapies.
Main Methods:
- Literature review of studies on aging, immunity, melanoma, and immunotherapy.
- Analysis of the tumor microenvironment in aging.
- Synthesis of current research on immune checkpoint inhibitors in older populations.
Main Results:
- Aging impacts immune cell function and the tumor microenvironment, potentially reducing immunotherapy effectiveness.
- Specific age-related immune alterations can be targeted to enhance treatment response.
- Understanding these interactions is crucial for personalized geriatric oncology.
Conclusions:
- Age-related immune changes significantly influence melanoma immunotherapy outcomes.
- Optimizing immunotherapies for older adults requires consideration of the aging immune system.
- Further research is needed to develop tailored strategies for geriatric cancer patients.
Related Concept Videos
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...